ROBERT HERSHBERG
CIK 1274139 · President and CEO · last filed 2026-09-11
ROBERT HERSHBERG is a President and CEO who has filed 74 SEC Form 4 insider transactions across 7 companies since 2015. The most recent filing, for ATAI, was dated Sep 11, 2026. Across all open-market trades the lifetime net is −$5.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.6M across reported positions. 2 SEC filings were submitted jointly with ATAI Life Sciences N.V.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.65M
7
74
-$5.24M
Filer Profile
BOSTON, MA 02118
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ATAI | Director | 100,000 | $7.35 | $735.0K | -$496.0K | 4 | 2026-09-11 |
| ADPT | Director | 77,347 | $29.40 | $2.27M | -$3.42M | 23 | 2026-08-20 |
| RXRX | Director | 162,156 | $3.79 | $613.8K | $0 | 10 | 2026-06-22 |
| HilleVax, Inc. (HLVX) Delisted | President and CEO | 0 | $2.09 | $0 | -$221.8K | 4 | 2025-09-17 |
| FATE | Director | 10,659 | $2.40 | $25.6K | -$15.3K | 5 | 2023-06-07 |
| ARS Pharmaceuticals, Inc. (SBTX) Delisted | Director | — | $5.87 | — | $0 | 3 | 2022-06-13 |
| NanoString Technologies Inc (NSTG) Delisted | Director | 10,716 | $0.11 | $1.1K | -$1.09M | 20 | 2022-04-18 |
Recent Filings
74 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-11 | ATAI | Disp (D) | — | $0 | EDGAR |
| 2026-08-20 | ADPT | Mixed | −15,664 | -$653.4K | EDGAR |
| 2026-08-18 | ADPT | Notice (144) | −30,664 | -$748.3K | EDGAR |
| 2026-07-09 | ATAI | Mixed | — | -$361.0K | EDGAR |
| 2026-07-07 | ATAI | Notice (144) | −100,000 | -$496.0K | EDGAR |
| 2026-06-22 | RXRX | Grant (A) | +88,424 | $0 | EDGAR |
| 2026-06-08 | ATAI | Grant (A) | — | $0 | EDGAR |
| 2026-03-06 | ADPT | Grant (A) | +15,625 | $0 | EDGAR |
| 2025-12-12 | ADPT | Sell (S) | −22,968 | -$367.5K | EDGAR |
| 2025-12-10 | ADPT | Notice (144) | −22,968 | -$367.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.